Abbvie
ABBV

Abbvie (ABBV) earnings history

Most recent quarter

Period end
Jun 30, 2026
Revenue
$17.0B
Reported
Jul 31, 2026

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2026Jul 31, 2026$3.60$3.65+1.40%$17.0BSEC
Q1 2026Apr 29, 2026$2.59$2.65+2.23%$15.0BSEC
Q4 2025Feb 4, 2026$2.65$2.71+2.15%$16.6BSEC
Q3 2025Oct 31, 2025$1.77$1.86+5.34%$15.8BSEC
Q2 2025Jul 31, 2025$2.88$2.97+3.12%$15.4BSEC
Q1 2025Apr 25, 2025$2.38$2.46+3.39%$13.3BSEC
Q4 2024Jan 31, 2025$2.12$2.16+2.12%$15.1BSEC
Q3 2024Oct 30, 2024$2.92$3.00+2.74%$14.5BSEC
Q2 2024Jul 25, 2024$2.57$2.65+3.29%$14.5BSEC
Q1 2024Apr 26, 2024$2.25$2.31+2.46%$12.3BSEC
Q4 2023Feb 2, 2024$2.79$2.79−0.11%$14.3BSEC
Q3 2023Oct 27, 2023$2.87$2.95+2.87%$13.9BSEC
Q2 2023Jul 27, 2023$2.83$2.91+2.75%$13.9BSEC
Q1 2023Apr 27, 2023$2.51$2.46−1.95%$12.2BSEC
Q4 2022Feb 9, 2023$3.56$3.60+1.10%$15.1BSEC
Q3 2022Oct 28, 2022$3.57$3.66+2.43%$14.8BSEC
Q2 2022Jul 29, 2022$3.32$3.37+1.49%$14.6BSEC
Q1 2022Apr 29, 2022$3.14$3.16+0.59%$13.5BSEC
Q4 2021Feb 2, 2022$3.28$3.31+0.81%$14.9BSEC
Q3 2021Oct 29, 2021$3.21$3.33+3.62%$14.3BSEC

Quarterly revenue

Q3 2021
$14.3B
Q4 2021
$14.9B
Q1 2022
$13.5B
Q2 2022
$14.6B
Q3 2022
$14.8B
Q4 2022
$15.1B
Q1 2023
$12.2B
Q2 2023
$13.9B
Q3 2023
$13.9B
Q4 2023
$14.3B
Q1 2024
$12.3B
Q2 2024
$14.5B
Q3 2024
$14.5B
Q4 2024
$15.1B
Q1 2025
$13.3B
Q2 2025
$15.4B
Q3 2025
$15.8B
Q4 2025
$16.6B
Q1 2026
$15.0B
Q2 2026
$17.0B

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.